6 completed, 1 active not recruiting. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Active not recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Eosinophilic enteropathy: new trials by email Literature Review of Eosinophilic enteropathy trials Research Report on Eosinophilic enteropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have Dupilumab - Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 22 | 2023-05-03 | 2026-07-01 |
| Dupilumab in Eosinophilic Gastritis Dupilumab (blinded), Placebo (blinded) - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 41 | 2021-05-15 | 2025-11-04 |
| An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis AK002 - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 2 | Completed | Allakos Inc. | 58 | 2018-11-14 | 2024-02-28 |
| A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis AK002, Placebo - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 2 | Completed | Allakos Inc. | 65 | 2018-07-18 | 2024-01-19 |
| Benralizumab for Eosinophilic Gastritis (BEGS) Benralizumab, Placebo - Eosinophilic Gastritis or Gastroenteritis | Phase 2 / Phase 3 | Completed | Children's Hospital Medical Center, Cincinnati | 26 | 2018-04-23 | 2022-02-03 |
| Omalizumab to Treat Eosinophilic Gastroenteritis Omalizumab - Gastroenteritis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2004-06-02 | 2017-07-02 |
| Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Mepolizumab - Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 24 | 2001-12-01 | 2020-07-29 |
Eosinophilic Esophagitis (4) · Gastroenteritis (2) · Churg-Strauss Syndrome (1) · Hypereosinophilic Syndrome (1) · Hypersensitivity (1)
Digestive System Diseases (6) · Gastrointestinal Diseases (6) · Immune System Diseases (5) · Eosinophilia (4) · Esophageal Diseases (4) · Esophagitis (4) · Gastroenteritis (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Hypersensitivity (4) · Hypersensitivity, Immediate (4) · Leukocyte Disorders (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Autoimmune Diseases (1) · Cardiovascular Diseases (1)
AK002 (2) · dupilumab (2) · Omalizumab (1) · benralizumab (1) · mepolizumab (1)
Children's Hospital Medical Center, Cincinnati (3) · Allakos Inc. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Regeneron Pharmaceuticals (1)
United States (7) · Canada (1) · Italy (1) · Japan (1)
Craig Paterson, MD (1) · Henrik Rasmussen, MD, PhD (1) · Marc E Rothenberg, MD, PhD (1) · Marc E. Rothenberg, MD (1) · Marc Rothenberg (1)
PMID 37753954, PMID 20004787, PMID 21527026, PMID 33085861, PMID 34089846, PMID 37336228, PMID 38423296, PMID 42341804
U54AI117804 (1)